Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2019.6803
Abstract: Key Points Question How frequently do immune checkpoint inhibitor (ICI) agents vs non-ICI agents qualify for American Society of Clinical Oncology Value Framework version 2 (ASCO-VF v2) tail-of-the-curve bonuses or European Society of Medical Oncology… read more here.
Keywords: immune checkpoint; oncology; checkpoint inhibitor; long term ... See more keywords
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells.
Sign Up to like & getrecommendations! Published in 2023 at "Advanced science"
DOI: 10.1002/advs.202204378
Abstract: Immune checkpoint inhibitor (ICI) clinically benefits cancer treatment. However, the ICI responses are only achieved in a subset of patients, and the underlying mechanisms of the limited response remain unclear. 160 patients with non-small cell… read more here.
Keywords: intracellular adhesion; checkpoint inhibitor; immune checkpoint; molecule ... See more keywords
Value of Onconeural Antibodies in Checkpoint Inhibitor‐Related Toxicities
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Neurology"
DOI: 10.1002/ana.25764
Abstract: Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities Alberto Vogrig, MD , Sergio Muñiz-Castrillo, MD , and Jérôme Honnorat, MD, PhD An increasing number of patients will be exposed to immune checkpoint inhibitors (ICIs) in… read more here.
Keywords: related toxicities; onconeural antibodies; antibodies checkpoint; value onconeural ... See more keywords
Checkpoint inhibitor/interleukin‐based combination therapy of cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4659
Abstract: Immunotherapy using immune checkpoint inhibitors (ICIs) is the current focus in cancer immunotherapy. However, issues are raised in the area, as the recent studies showed that such therapeutic modality suffers from low durability and low… read more here.
Keywords: combination; checkpoint inhibitor; cancer; combination therapy ... See more keywords
Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5085
Abstract: Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low… read more here.
Keywords: checkpoint inhibitor; immune checkpoint; combined immune; hyperthermia combined ... See more keywords
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5796
Abstract: The effectiveness and safety of immune checkpoint inhibitor (ICI) monotherapy in advanced upper tract urothelial carcinoma (UTUC) is less reported. read more here.
Keywords: safety immune; checkpoint inhibitor; immune checkpoint; monotherapy advanced ... See more keywords
Feasibility of supervised telehealth exercise for patients with advanced melanoma receiving checkpoint inhibitor therapy.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6091
Abstract: PURPOSE To determine the feasibility, safety and preliminary efficacy of a telehealth supervised exercise programme in patients with advanced melanoma receiving checkpoint inhibitor therapy. METHODS A 8-week non-randomised feasibility pilot trial utilising a telehealth delivered… read more here.
Keywords: advanced melanoma; checkpoint inhibitor; patients advanced; telehealth ... See more keywords
Heterogeneity of Checkpoint Inhibitor–Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.71041
Abstract: Checkpoint inhibitor–associated pneumonitis (CIP) is a serious manifestation following tumor immunotherapy, typically mediated by T lymphocytes. However, the heterogeneity in blood inflammatory profiles and its implications on clinical characteristics and outcomes for CIP remain underexplored. read more here.
Keywords: inhibitor associated; checkpoint inhibitor; associated pneumonitis;
Immune Checkpoint Inhibitor‐Related Myocarditis: A Single Center Observational Registry
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cardiology"
DOI: 10.1002/clc.70154
Abstract: Immune checkpoint inhibitors (ICIs) are associated with myocarditis, which is rare but has a high mortality. This study aimed to describe cases of ICI‐related myocarditis at the University of Iowa Hospitals & Clinics and, in… read more here.
Keywords: related myocarditis; immune checkpoint; checkpoint inhibitor; inhibitor related ... See more keywords
Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34543
Abstract: Gastrointestinal immune‐related adverse events are frequently caused by immune checkpoint inhibitors (ICIs) and often require interruption of cancer treatment. Compared with ICI colitis and enteritis, limited information exists about ICI gastritis. This study characterized clinical… read more here.
Keywords: checkpoint inhibitor; immune checkpoint; gastritis; inhibitor gastritis ... See more keywords
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor
Sign Up to like & getrecommendations! Published in 2024 at "Cancer"
DOI: 10.1002/cncr.35302
Abstract: Rechallenge with antibodies targeting programmed cell death protein‐1 or its ligand (PD‐1/L1) after discontinuation or disease progression in solid tumors following a prior PD‐1/L1 treatment is often practiced in clinic. This study aimed to investigate… read more here.
Keywords: immune checkpoint; cell; patients metastatic; checkpoint inhibitor ... See more keywords